Dapagliflozin prevented the progression of diabetic kidney disease by inhibiting cellular senescence and oxidative stress via ketone-induced NRF2 activation (Diabetes, Obesity and Metabolism)
Diabetes News
Tag: DKD
Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
Model results suggest that adding canagliflozin 100 mg to SoC can improve patient outcomes while reducing overall net costs from the NHS perspective in England (Diabetes Therapy)
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
SGLT2 inhibitors show great promise for prevention and treatment of DKD. Trials with empagliflozin have demonstrated, for the first time, a reduction in all-cause and cardiovascular mortality in patients with T2D and CKD (Diabetes)
Interactions between kidney disease and diabetes: dangerous liaisons
Understanding the renal physiology and pathophysiology of DKD has become essential to all specialties treating diabetic patients (Diabetology & Metabolic Syndrome)
Early renin-angiotensin-system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes
RAS intervention early in the course of proteinuric DKD is more beneficial than late intervention in delaying ESRD (Diabetes, Obesity and Metabolism)
Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets
The purpose of this review is to describe the current understanding of how the hemodynamic, metabolic, inflammatory, and alternative pathways are all entangled in pathogenesis of DKD and detail the various therapeutic targets that may one day play a role in quelling this epidemic (Journal of Diabetes Research)
Glycosmedia is also available as an App: